Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy.
Bartneck J, Hartmann AK, Stein L, Arnold-Schild D, Klein M, Stassen M, Marini F, Pielenhofer J, Meiser SL, Langguth P, Mack M, Muth S, Probst HC, Schild H, Radsak MP.
Bartneck J, et al. Among authors: hartmann ak.
Front Immunol. 2023 Oct 2;14:1267866. doi: 10.3389/fimmu.2023.1267866. eCollection 2023.
Front Immunol. 2023.
PMID: 37849753
Free PMC article.